Author: j3ff1

Home Articles Posted by j3ff1

132 posts, 0 comments

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

August 4, 2026

RespireRx Press Release Letter to Stockholders and Other Interested Parties 08042026 final finalDownload

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

November 20, 2025

RespireRx Press Release Letter to Stockholders and Other Interested Parties 08042026 final finalDownload

RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement

November 19, 2025

RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement

November 18, 2025

RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common Stock

November 18, 2025

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

February 10, 2025

5/29/24 – RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury

May 29, 2024

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

March 26, 2024

RespireRx-SCI-Bladder-paper-final-approved-for-distributionDownload

2/13/24 – RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

February 13, 2024

1/22/24 – RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors

January 22, 2024